Gensciences Group announced the closing of over RMB 800 million in Series A and B financings. The B round financing was led by HT Capital, with participation from Efung Capital and Huarong Rongde. Existing A round shareholders IDG Capital, New Alliance Capital, and Hygeia Capital also continued to support the company. The funds raised in this round will be used to further support the development and clinical research of the company's biologics drugs, the construction of production workshops, and the commercialization of its products.

CEC Capital Group served as the exclusive financial advisor for Gensciences Group in both the A and B round financings.